MXPA06011218A - Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. - Google Patents

Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion.

Info

Publication number
MXPA06011218A
MXPA06011218A MXPA06011218A MXPA06011218A MXPA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A
Authority
MX
Mexico
Prior art keywords
cells
compound
ppar
disease
invitrogen
Prior art date
Application number
MXPA06011218A
Other languages
English (en)
Spanish (es)
Inventor
Anne Minnich
Jean Merrill
Olga Khorkova
Karen Chandross
Lan Lee
Yun Liu
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MXPA06011218A publication Critical patent/MXPA06011218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06011218A 2004-04-01 2005-03-29 Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. MXPA06011218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
MXPA06011218A true MXPA06011218A (es) 2007-01-16

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011218A MXPA06011218A (es) 2004-04-01 2005-03-29 Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion.

Country Status (16)

Country Link
US (1) US20070149580A1 (enExample)
EP (1) EP1737440A2 (enExample)
JP (1) JP2007530703A (enExample)
KR (1) KR20060134191A (enExample)
CN (1) CN1950077A (enExample)
AU (1) AU2005231358A1 (enExample)
BR (1) BRPI0509540A (enExample)
CA (1) CA2561159A1 (enExample)
IL (1) IL178165A0 (enExample)
MA (1) MA28561B1 (enExample)
MX (1) MXPA06011218A (enExample)
NO (1) NO20064985L (enExample)
RU (1) RU2006138495A (enExample)
SG (1) SG138623A1 (enExample)
WO (1) WO2005097098A2 (enExample)
ZA (1) ZA200607850B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
CN101336113B (zh) * 2005-11-28 2015-07-29 千寿制药株式会社 包括ppar激动剂的药物
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
CA2727373A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US20130117868A1 (en) 2009-12-17 2013-05-09 Sanofi Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
NO20064985L (no) 2006-10-31
WO2005097098A2 (en) 2005-10-20
KR20060134191A (ko) 2006-12-27
CN1950077A (zh) 2007-04-18
IL178165A0 (en) 2008-03-20
US20070149580A1 (en) 2007-06-28
SG138623A1 (en) 2008-01-28
BRPI0509540A (pt) 2007-09-18
CA2561159A1 (en) 2005-10-20
JP2007530703A (ja) 2007-11-01
WO2005097098A3 (en) 2005-12-22
MA28561B1 (fr) 2007-04-03
AU2005231358A1 (en) 2005-10-20
ZA200607850B (en) 2008-10-29
RU2006138495A (ru) 2008-05-10
EP1737440A2 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
Wu et al. Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors
Granneman et al. Member of the peroxisome proliferator–activated receptor family of transcription factors is differentially expressed by oligodendrocytes
MXPA06011218A (es) Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion.
AU2011296080B2 (en) Composition and method for muscle repair and regeneration
US20150119327A1 (en) Drug screening platform for rett syndrome
EP2806948B1 (en) Method for enhancing remyelination using gli1 inhibitors
JP2010528016A (ja) 細胞を刺激するための方法および組成物
Jana et al. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β
WO2015069736A1 (en) METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US7132287B2 (en) Method for neural stem cell differentiation using 5HT-1A agonists
US20170196839A1 (en) Neurodegenerative diseases and methods of modeling
US20040092010A1 (en) Method of proliferating and inducing brain stem cells to differentiate to neurons
Jana et al. IL‐12 p40 homodimer, the so‐called biologically inactive molecule, induces nitric oxide synthase in microglia via IL‐12Rβ1
Yao et al. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes
EP3615022B1 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
Timmer et al. The activin signaling pathway promotes differentiation of dI3 interneurons in the spinal neural tube
Hu et al. The molecular events involved in oligodendrocyte precursor cell proliferation induced by the conditioned medium from B104 neuroblastoma cells
HK40080448B (en) Retinoic acid receptor gamma agonists for muscle repair and regeneration
US20210186903A1 (en) Treatment for demyelinating disease
HK40036876A (en) Composition and method for muscle repair and regeneration
HK40080448A (en) Retinoic acid receptor gamma agonists for muscle repair and regeneration
Li The mechanisms of ethanol-induced damage to the developing cerebellum: Effects on the cerebellar granule cells
Van Heyningen Control of glial progenitor cell number in the developing central nervous system
Redwine The in vivo PDGF response during remyelination in mouse spinal cord following murine hepatitis virus strain A59-induced transient demyelination
Bennett Perturbations in oligodendrocyte progenitor growth and differentiation: Neurofibromin and FGF2 signaling

Legal Events

Date Code Title Description
FA Abandonment or withdrawal